The 11β-hydroxysteroid dehydrogenase type 1 inhibitor SPI-62 prevents morbidity in a mouse model of Cushing's syndrome
X. Pan, Q. Hou, J. Su, J. Xu, M. Li, J. Li, X. Shi, C. Schmicker, T. Magers, W. M. Bracken, D. A. Katz
SPI-62, an HSD-1 inhibitor, reduces GC-induced morbidity in a mouse Cushing's syndrome model by improving insulin sensitivity, reducing adiposity, and preventing skeletal myopathy.
bioRxiv · May 27, 2024 · PreprintPharmacology & Toxicology